Latest News and Press Releases
Want to stay updated on the latest news?
-
SAN DIEGO, Aug. 12, 2014 (GLOBE NEWSWIRE) -- Lithera, Inc., announced today that it has changed its name to Neothetics, Inc. The new name strengthens the company's positioning as a clinical-stage,...
-
SAN DIEGO, April 2, 2014 (GLOBE NEWSWIRE) -- Lithera, Inc. ("Lithera" or "the Company"), a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and...
-
SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Lithera, Inc. ("Lithera" or "the Company"), a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and...
-
SAN DIEGO, Feb. 11, 2014 (GLOBE NEWSWIRE) -- Lithera, Inc. ("Lithera" or "the Company"), a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and...
-
SAN DIEGO, Nov. 21, 2013 (GLOBE NEWSWIRE) -- Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today...
-
SAN DIEGO, Sept. 30, 2013 (GLOBE NEWSWIRE) -- Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today...
-
SAN DIEGO, July 18, 2013 (GLOBE NEWSWIRE) -- Lithera, Inc. ("Lithera" or "the Company"), a clinical stage pharmaceutical company focused on aesthetic and medical indications, today announced that it...
-
SAN DIEGO, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering formulations and...
-
SAN DIEGO, Dec. 19, 2012 (GLOBE NEWSWIRE) -- Lithera, Inc. today announced investment of $20.6 million in preferred stock equity financing. Additional investment may provide the Company with up to a...
-
SAN DIEGO, April 4, 2011 (GLOBE NEWSWIRE) -- Lithera, Inc. announced today the appointment of Thomas G. Wiggans to its Board of Directors. "Lithera is making substantial progress with LIPO-102 by...